Instituto D'Or de Pesquisa e Ensino - Hospital Sao Rafael

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Sickle cell disease3 trials
• Lung cancer2 trials
• Friedreich ataxia1 trial
• Lupus (SLE)1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Recruiting3 trials
• Terminated2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Pfizer4 trials
• Amgen1 trial
• Autolus Limited1 trial
• Lexeo Therapeutics1 trial

Running trials

• Recruiting

  Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  NCT07053800· Phase 2· Autolus Limited· Source

  Contact: Autolus Ltd

• Recruiting

  Clinical Course Of Disease In Participants With FA-CM

  NCT06865482· Lexeo Therapeutics· Source

  Contact: Lexeo Clinical Trials

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Friedreich ataxia1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting

Closed trials

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source